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Objectives: To review clinical guidelines, recent HTA decisions, and the influ-
ence of economic analyses in HTA decisions related to biologic therapies in 
UC. MethOds: A literature review and targeted research provided information 
on clinical treatment guidelines (US and Europe) and HTAs (Europe) related to 
biologics in UC. Economic models in UC were identified and reviewed to deter-
mine how these affected HTA decisions. Results: Since several biologics were 
approved after the last version of the US treatment guidelines, the US guidelines 
only address the use of infliximab for the treatment of moderate or severe UC. 
In the UK, NICE has recommended infliximab, adalimumab, and golimumab as 
possible treatments for adults with moderate to severe UC in whom conventional 
therapy hasn’t worked or isn’t suitable. A recent NICE HTA recommends vedoli-
zumab as an option for treating moderately to severely active UC in adults only 
if the company provides vedolizumab with the discount agreed in the patient 
access scheme. The Scottish Medicines Consortium (SMC) recommends vedoli-
zumab for the treatment of adult patients with moderate-to-severe UC and an 
inadequate response, lost response, or intolerance to conventional therapy or a 
TNFα antagonist; this advice is “contingent upon the continuing availability of the 
patient access scheme in NHS Scotland or a list price that is equivalent or lower.” 
Earlier SMC advice did not recommend adalimumab, golimumab or infliximab 
for use within NHS Scotland due to lack of robust economic analyses. The SMC 
advice is superseded by the NICE HTA decisions. cOnclusiOns: In the UK and 
Scotland, more than 9 HTA have been performed in the 10 years since biologics 
have become available for the treatment of moderate-to-severe UC. Differential 
cost-effectiveness among specific indications, lines of treatment, and countries 
have resulted in a variety of recommendations as to their use which supplement 
clinical guidelines in UC.
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Objectives: The objective of this study was to describe the real-world use of 
adalimumab (ADA) for maintenance treatment of ulcerative colitis (UC) on a 
national level in Sweden. MethOds: A longitudinal, retrospective cohort study 
was conducted using the National Drug Registry and the National Patient Registry. 
UC patients (age ≥ 18 years) treated with ADA were included. Two cohorts were 
selected: (1) ADA naïve patients and (2) a cross-sectional cohort. Both cohorts were 
followed for a 12-month period. Dose escalation among the ADA naïve patients 
was defined as doubling of dose (ADA 40 mg every week) or having two follow-
ing filled prescriptions with average biweekly dose (ABD) ≥ 50 mg. Dosing in the 
cross-sectional cohort was assessed studying annual number of injections dis-
pensed among patients on maintenance treatment. Results: Five hundred and 
eighty-seven patients were identified as ADA naive during Jan 2010-April 2014. 
Dose-escalation by doubling of dose was observed in 273 (46.5%) patients with 
the median time to dose escalation being 84 days. Further analysis revealed that 
191 patients (32.5%) in the ADA naive patient cohort dose-escalated defined as 
(ABD) ≥ 50 mg, and of these 40 (20.9%) had a subsequent dose de-escalation which 
occurred after a median time of 162 days. In total 992 UC patients were identified 
in the cross-sectional cohort, defined as filling at least one prescription during May 
2013-April 2014, and of these 364 (37%) were on maintenance treatment. Out of the 
364 patients on maintenance treatment dispensing at least 22 injections during 
the period 140 (38%) received 30 injections or more. cOnclusiOns: This study 
demonstrates that UC patients receiving ADA in general have a patchy prescrip-
tion pattern, and that the proportion of patients who dose escalate is high. This 
finding and the impact that dose escalation has on costs may have implications 
for healthcare professionals and budget holders.
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Objectives: The purpose of this study is to assess the impact on physician pre-
scription behaviors of an outpatient prescription incentive program providing 
financial rewards to primary care physicians for saving prescription costs imple-
mented in October 2010 in South Korea. MethOds: A 10% sample of clinics 
(N= 1,625) was randomly selected from the entire clinics in the National Health 
Insurance claims database for the years 2009~2012, and all claims with the primary 
diagnosis of peptic ulcer or gastro-esophageal reflux diseases were extracted from 
those clinics’ data. We used a clinic-level random effects model analyzing policy 
effects on drug expenditures and prescribing behaviors including prescription rate 
of medicines treating target diseases, number of drug prescribed per claim, prescrip-
tion duration per claim. We also performed subgroup analyses by selected clinic 
characteristics, including practice type, size and specialty. Results: We found no 
significant impact of the program on drug expenditure overall. Prescription rate 
of target medicines increased and the average prescription duration per claim 
decreased after the incentive program. After the financial incentive program, clin-
ics in general medicine showed a lower prescription rate (by 0.8 percentage points), 
lower number of medicines prescribed (by 0.02), a lower prescription duration (by 
0.15 days), and lower drug expenditure per claim after the policy (by 740 won). Small 
clinics had shorter prescription duration (by 0.76 days), while large clinics and clinics 
in group practice had a higher prescription rate (by 1.5 and 2.5 percentage points, 
respectively) and higher number of medicines prescribed (by 0.03 for group practice 
only) after the program. cOnclusiOns: The financial incentive program worked as 
intended only in certain subgroup clinics for the target medicines. The reduction in 
prescription duration and the number of prescribed medicines in target claims in 
selected subgroups imply some margin for prescription adjustments.
quality of clinical evidence originating from same studies has been rated differ-
entially by different agencies. The economic evidence in this area was primarily 
based on cost-effectiveness/cost utility analysis (CEA/CUA), comprising ~95% of 
studies (time horizon 50 years to lifetime). The incremental cost-effectiveness 
ratios (ICER) ranged USD15000-200000 in PBAC, USD1246-376723 in NICE, USD750-
45200 in SMC, and USD11000-75000 in CADTH. More than 90% of the decisions 
based on ICER values were positive, with restriction being focused on cost negotia-
tions. The primary driver of positive decisions was majorly economic analysis in 
NICE, PBAC, and SMC, while clinical evidence drove positive recommendations in 
CADTH, IQWiG, and HAS. cOnclusiOns: Current landscape of CHC treatments 
in Canada, Australia, UK, Scotland, Germany, and France is majorly dominated 
by positive recommendations, considering the high unmet in this area. Most of 
the restrictions were around cost negotiations. The drivers of decisions fit with 
agency priorities, with economic analysis being the key driver in agencies with 
pharmacoeconomic analysis, and clinical evidence in agencies without pharma-
coeconomic analysis.
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Objectives: To compare the regulatory label indications and health technology 
assessment (HTA) recommendations for therapies indicated for the treatment of 
chronic hepatitis-C (CHC). MethOds: We reviewed the regulatory labels approved 
by European Medicines Agency (Europe), Health Canada (Canada) and Therapeutic 
Goods Administration (Australia). HTA reports for CHC therapies published by 
NICE (England and Wales), SMC (Scotland), HAS (France), IQWiG (Germany), CADTH 
(Canada) and PBAC (Australia) were assessed. Therapies with a positive HTA deci-
sion (recommended or restricted) were included in the analysis. Indication was 
split into four categories: age of the population (children, adults or both), fibrosis 
status (cirrhotic or non-cirrhotic), genotype, and prior treatment history (naïve or 
treatment-experienced). A match was defined as overlap of HTA and regulatory 
decision for any of the categories. Percentage correlation of the HTA indication 
with the regulatory label was calculated as the ratio of actual matches to the 
maximum possible matches for the parameters considered. Results: A total 
of 34 regulatory approvals and 48 HTA reports were identified from the public 
domain. Forty-six HTA reports providing a positive decision were included. Overall, 
HTA decisions correlated well with the marketing authorization (89%), with the 
highest correlation observed for CADTH and PBAC (100% each), followed by HAS 
(98%), NICE and SMC (86% each) and IQWiG (63%). Across agencies, highest cor-
relation was observed for age of the population (96% cases) and lowest for the 
prior treatment history (85% cases) of the population for whom the therapies were 
recommended. cOnclusiOns: Overall, the indication approved by HTA agency 
almost correlated completely with the indication granted marketing authoriza-
tion, except for NICE, SMC and IQWiG, indicating difference in agency priorities 
driving HTA decisions. Analyzing the population restriction applied by NICE, SMC 
and IQWiG would provide the decision drivers, allowing manufacturers to address 
these concerns in prospective submissions.
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Objectives: Recent advances in the management of hepatitis C virus (HCV) have 
yielded therapeutic modalities that are more efficacious, better tolerated, and have 
a lower pill and injection burden. Given the large population affected by HCV, deci-
sions by health technology assessment (HTA) bodies weigh significantly in terms 
of societal benefits and expenditures. The objective of this analysis was to evaluate 
recent patterns in HCV-related HTA decisions in selected countries. MethOds: 
HTA surveillance was conducted for Australia, Canada, France, Germany, and the 
United Kingdom (UK) from January 1, 2012 to June 1, 2015 (42 months). HTAs for 
HCV treatments were evaluated by genotype, decision, and decision rationale. 
Decisions were categorized as favorable, unfavorable, mixed (both favorable and 
unfavorable), and neutral (deferral). Results: 32 HCV-related HTAs were pub-
lished in the study time frame, with 7 assessments currently in development. 
Among the completed assessments, the majority of decisions were favorable (24, 
75%), with only 2 (6%) unfavorable and 6 (19%) mixed decisions. The most com-
mon rationales provided for a negative decision included insufficient data and/
or inappropriate comparators (4), insufficient benefit to justify the high cost (ie, 
improperly high incremental cost-effectiveness ratio [ICER]) (3), and inadequate 
clinical benefit vs the most appropriate comparator (1). France and Canada had 
the highest percentage of favorable decisions (5 of 5 and 9 of 9, respectively, 
100%), followed by the UK (3 of 4, 75%), Australia (5 of 8, 63%), and Germany (2 
of 6, 33%). cOnclusiOns: Based on the last 42 months of HCV-related HTAs, 
75% of decisions were favorable. However, the most significant factors leading to 
unfavorable assessments for HCV products are related to the inability to supply 
advantageous clinical and cost-effectiveness data. This analysis suggests that 
manufacturers would have greater success with HTA decisions if more robust 
health economic and clinical data are generated.
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Objectives: To develop and validate predictive models for estimating risk of early 
diagnosis of knee osteoarthritis (OA) by weighted cumulative exposure (WCE) 
function scores of prior knee pain consultations. MethOds: Both derivation and 
validation datasets were from an electronic healthcare record (EHR) database 
(Consultations in Primary Care Archive [CiPCA]) in England. WCE functions for 
modelling cumulative effect of time-varying knee pain consultations weighted by 
recency was derived as predictive tool in a population based case-control sample 
and validated in a prospective cohort sample. Two sets of WCE function scores: 
WCE (Half-Normal) score and WCE (Spline) score were evaluated and compared 
on model fitness, discrimination, and calibration both in derivation and validation 
phases. Results: People with the most recent and the most frequent knee pain 
consultations were more likely to have high WCE scores (both sets) and these were 
associated with increased risk of knee OA diagnosis both in derivation and valida-
tion phases. Better model fit, discrimination, and calibration were observed for 
models with WCE (Spline). cOnclusiOns: WCE functions can be used to model 
pre-diagnostic symptoms within routine EHR data and may provide novel low-cost 
predictive tools that may contribute to early diagnosis.
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Objectives: To assess the relative efficacy of bisphosphonates (alendronate, risedro-
nate, ibandronate and zoledronate) for the treatment of Osteoporosis using network 
meta-analysis (NMA). MethOds: A systematic review of the literature was conducted 
using PRISMA guidelines. A network meta-analysis was used to determine the relative 
efficacy of treatments on four fracture outcomes (vertebral, non-vertebral, hip and 
wrist) and percentage change in femoral neck bone mineral density (BMD). Treatment 
effects were modelled using an exchangeable treatment effects model. Heterogeneity 
in treatment effects was explored by considering potential treatment effect modifiers 
using meta-regression. Where appropriate, inconsistency between direct and indirect 
evidence was assessed using node-splitting. Results: 46 randomised controlled tri-
als (RCTs) were identified. Twenty seven RCTs provided fracture data and 35 RCTs 
provided BMD data for analysis. Zoledronate was associated with the greatest treat-
ment effect on vertebral fractures (HR 0.41, 95% CrI 0.28-0.56) and percentage change 
in BMD (3.21, 95% CrI 2.52-3.86) compared to Placebo. The greatest treatment effect on 
non-vertebral and wrist fractures was given by risedronate (HR 0.72, 95% CrI 0.53-0.89 
and HR 0.77, 95% CrI 0.44-1.24, respectively). For hip fractures the greatest treatment 
effect was given by alendronate (HR 0.78, 95% CrI 0.44-1.30). cOnclusiOns: All treat-
ments were associated with beneficial effects on fractures and femoral neck BMD 
relative to placebo. For vertebral fractures and percentage change in BMD the treat-
ment effects were statistically significant for all treatments. Pairwise comparisons 
between treatments indicated that no active treatment was statistically significantly 
more effective than any other active treatment for fracture outcomes. There was some 
heterogeneity in treatment effects between studies suggesting differential treatment 
effects according to study characteristics However, there was no evidence of differ-
ential treatment effects with respect to gender and age.
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Objectives: Risk of end-stage renal disease (ESRD) in both hypertension and 
gout has been examined in the literature. However, the impact of allopurinol 
adherence on primary prevention of ESRD has not been assessed. The objective is 
to evaluate impact of better allopurinol adherence on ESRD onset. MethOds: A 
cohort of 2752 patients with gout diagnosis was reconstructed using the Québec 
RAMQ and MED-ECHO administrative databases. New users of allopurinol, aged 
45-85 years, with a diagnosis of hypertension and treated with an antihypertensive 
drug between 1997-2007 were eligible. A nested case-control design was used to 
study ESRD occurrence. Every ESRD case was matched for age, sex and duration 
of follow-up for up to 15 controls. Adherence level was assessed as medication 
possession ratio. Conditional logistic regression models were used to estimate rate 
ratios (RR) of ESRD adjusting for covariables. Results: Patients had a mean age 
of 68 years, 82% were men, approximately 50% had ≥ 1 cardiovascular disorder, 
33% had dyslipidemia, 21% had diabetes, 15% had chronic kidney disease, and 
21%, 33%, and 42% were taking thiazides, low-dose aspirin, and NSAIDs, respec-
tively. Clinical characteristics were similar among allopurinol adherent versus 
non-adherent patients. Major risk factor for ESRD onset was chronic kidney dis-
ease at stages 1-3 (RR: 8.00; CI: 3.16 -22.3), and hypertension severity (≥ 3 vs. < 3 
antihypertensive treatments) was a trending risk factor as a crude estimate (RR: 
1.94; CI: 0.68-5.51). Of 341 patients (cases, n= 22; controls, n= 319), high adherence 
(≥ 80%) to allopurinol, versus lower adherence (< 80%), was associated with a lower 
rate of ESRD onset (RR: 0.35; confidence interval [CI]: 0.13-0.91). cOnclusiOns: 
This population-based study suggests that better allopurinol adherence may be 
associated with risk reduction of new-onset ESRD in hypertensive patients. Further 
research is needed, as this study was limited by the small number of cases and 
potential residual confounding factors.
mUscUlar-sKeletal DIsorDers – clinical outcomes studies
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Objectives: Postoperative blood-saving is high-priority after every planned surgery. 
The aim of this study was to analyse the effect of positioning of lower extremities on 
the postoperative bleeding after total knee replacement surgery. MethOds: Sixty 
patients from the orthopaedic department of Zala County Hospital who were operated 
on for insertion of a unilateral total knee prosthesis with cement and got autologous 
blood transfusion (age 35-80 years), were randomly assigned to three intervention 
groups. In Group I (n= 20), patients were in normal laying position, in Group II (n= 20), 
hips were positioned in flexion and knee in extension and in Group III (n= 20), hips and 
knees were positioned in 30o flexion in the first 6 postoperative hours. The surgical 
technique, the surgeon and the anticoagulant treatments were the same. Data col-
lection: medical records, haemoglobin and haematocrit. For the clinical parameters, 
t-tests, ANOVA and Scheffe post hoc tests were used. Statistical significance was estab-
lished at the α -level of 0.05, and IBM SPSS 20.0v was used. Results: During the first 
six postoperative hours positioning not affected significantly on the volume of bleed-
ing and recirculated blood volume (Group I: 615.0±247.3, Group II: 600.0±358.2, Group 
III: 715.0±392.3 ml, ANOVA: p= 0.714; post hoc: p1-2= 0.995, p1-3= 0.805, p 2-3= 0.751), 
either in hours 6-72 (Group I: 775.0±227.6, Group II: 762.0±332.8, Group III: 960.0±400.6 
ml, p= 0.335; p1-2= 0.996, p1-3= 0.462, p2-3= 0.414). Most units of homologous transfu-
sion were needed in Group II (10 units). Position had not effect on the intensity of pain 
and value of the active range of motion of the knee (p= 0.682 vs. p = 0.585) either in 
haemoglobin and haematocrit values (p= 0.362 vs. p= 0.559). cOnclusiOns: These 
results of the present study suggest that the postoperative positioning of the lower 
extremities after knee replacement not affected the postoperative bleeding, the pain 
and the range of motion of the knee joint.
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Objectives: Patients with rheumatoid arthritis (RA) have a higher risk of ischemic 
cardiac events compared with the general population. This would be explained 
not only by the greater presence of traditional risk factors, but also by the sys-
temic inflammatory nature of arthritis. To compare the prevalence of ischemic 
heart disease (IHD) in a target RA population with the international prevalence 
data. MethOds: Cross-sectional study including 183 adult patients with code M05-
M06 (ICD-10) attended in primary or secondary care units from Blumenau city, 
southern Brazil, in 2014. Data collection was performed through structured personal 
interview and, if necessary, later by phone. The presence of IHD was defined as 
acute myocardial infarction, unstable angina, percutaneous coronary intervention or 
coronary artery bypass graft that have occurred after the diagnosis of RA. Results: 
153/183 patients were female (83.6%), mean age of 56.9 years and disease mean 
duration of 12.1 years. The number of cases with first acute myocardial infarction, 
unstable angina or myocardial revascularization after the diagnosis of rheumatoid 
arthritis was 7 (3.8%), two men and five women, two of those fatal, one of each sex. 
When the international prevalence are in Denmark 2.6%, Sweden 3.3%, Netherlands 
3.8%, UK 4.8%, France 4.1%, Canada 3.5%, US 3.7%, China 3.5%, Russia 5.1%, New 
Zealand 5.2%. cOnclusiOns: The result shows that the prevalence of coronary 
ischemia in patients with rheumatoid arthritis from Blumenau is similar to the 
prevalence observed in other countries.
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Objectives: Depression is a chronic debilitating disease with high prevalence that 
considerably affects quality of life. The relationship between depression and osteo-
porosis has been demonstrated, but the evidence is heterogeneous. The aim of the 
present study is to investigate about this relationship in the Italian primary care set-
ting. MethOds: This was a retrospective analysis based on data extracted from Italian 
IMS Health Longitudinal Patient Database. Two cohorts have been defined: patients 
with a diagnosis of Depression (Index Date) during the period January 2004 - December 
2010 and without neither Depression neither Osteoporosis diagnosis during the 5 years 
period preceeding the Index Date; patients with a first contact (Index Date) during the 
period January 2004 - December 2010 that are not in the previous cohort (free from 
Depression) and without neither Osteoporosis neither Depression diagnosis during 
the five years period preceeding the Index Date. Patients in both the two cohorts have 
been followed-up until one of the following event occurred first: Osteoporosis diagnosis 
registration, death, end of registration with the GP, 31 December 2013. Osteoporosis 
incidence rates have been separately calculated in the two cohorts and Osteoporosis 
cumulative incidence curves have been estimated using Kaplan Meier methods and 
compared performing log rank tests. Both univariate and multivariate Cox proportional 
hazard models were performed. Results: Osteoporosis incidence was higher in the 
cohort of depressed patients (2.33 cases per 100 person years vs 1.22 cases per 100 
person years) and results were confirmed by the log rank test (p< 0.001). Increased 
risk of developing osteoporosis for depressed patients was shown both by univariate 
proportional hazard model (HR= 1.75, CI= [1.72,1.78]) and multivariate proportional 
hazard model (HR= 1.15, CI= [1.13, 1.17]). cOnclusiOns: Results from this study sug-
gests that the relationship between Depression and Osteoporosis is confirmed also 
in the primary care setting in Italy.
